{"id":22328,"date":"2024-01-16T10:10:19","date_gmt":"2024-01-16T15:10:19","guid":{"rendered":"https:\/\/medicarereport.org\/?p=22328"},"modified":"2024-01-16T10:10:20","modified_gmt":"2024-01-16T15:10:20","slug":"floridas-plan-to-import-prescription-drugs-from-canada-the-first-of-its-kind-may-face-obstacles-that-could-delay-implementation-and-savings","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=22328","title":{"rendered":"Florida\u2019s Plan to Import Prescription Drugs from Canada, the First of its Kind, May Face Obstacles that Could Delay Implementation and Savings"},"content":{"rendered":"\n<p>(Contact Chris Lee at The Kaiser Family Foundation published Jan. 12, 2024)<\/p>\n\n\n\n<p>A new KFF policy watch explains some of the hurdles the state of Florida still must clear before it can implement its novel plan to make some prescription drugs more affordable by importing them from Canada.  Continue reading <a href=\"https:\/\/www.kff.org\/health-costs\/press-release\/floridas-plan-to-import-prescription-drugs-from-canada-the-first-of-its-kind-may-face-obstacles-that-could-delay-implementation-and-savings\/\" data-type=\"link\" data-id=\"https:\/\/www.kff.org\/health-costs\/press-release\/floridas-plan-to-import-prescription-drugs-from-canada-the-first-of-its-kind-may-face-obstacles-that-could-delay-implementation-and-savings\/\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"147\" height=\"138\" class=\"wp-image-7499\" style=\"width: 147px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/07\/Kaiser-Family-Foundation.jpg\" alt=\"\"><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>&nbsp;The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Contact Chris Lee at The Kaiser Family Foundation published Jan. 12, 2024) A new KFF policy watch explains some of<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,21,20,15],"tags":[1015,76,65],"class_list":["post-22328","post","type-post","status-publish","format-standard","hentry","category-fda","category-health-care-finance","category-health-care-redesign","category-part-dprescription-drugs","tag-drug-imports","tag-fda","tag-medicare-part-d"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22328"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22328\/revisions"}],"predecessor-version":[{"id":22329,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/22328\/revisions\/22329"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}